FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029795370> ?p ?o ?g. }

• W2029795370 endingPage "2778" @default.
• W2029795370 startingPage "2765" @default.
• W2029795370 abstract "The pharmacodynamic characteristics of antibiotics should be considered when choosing empiric dosage regimens for the treatment of pneumonia.This study compared the probabilities of achieving requisite pharmacodynamic exposure (ie, f T > MIC, AUC/MIC) for antibiotics given for the empiric treatment of hospital-acquired pneumonia (HAP) as recommended by the 2005 guidelines of the American Thoracic Society and the Infectious Diseases Society of America.In a 5000-patient Monte Carlo simulation, pharmacodynamic analyses were performed for standard doses of cefepime, ceftazidime, ceftriaxone, ciprofloxacin, ertapenem, imipenem, levofloxacin, meropenem, and piperacillin/tazobactam. Prolonged 3-hour infusion regimens were also evaluated for anti-pseudomonal beta-lactams. MIC data were incorporated from the 2007 Meropenem Yearly Susceptibility Test Information Collection, a national surveillance study. The weighted cumulative fraction of response (wCFR) against common pneumonia pathogens was determined for each regimen. A second scenario was conducted by altering the pathogen prevalence to assess wCFR for late-onset pneumonia (ie, HAP in patients with prolonged mechanical ventilation). Optimal wCFR was defined a priori as >or=90%.Among the 0.5-hour infusions, cefepime, ceftazidime, and meropenem had the highest wCFRs (>or=90%) against pathogens that cause HAP (cefepime, 1 g q8h, 92.8%; 2 g q8h, 97.2%; 2 g q12h, 94.3%; ceftazidime, 2 g q8h, 93.2%; meropenem, 1 g q8h, 90.9%; 2 g q8h, 93.9%). Imipenem (500 mg q6h, 85.5%; 1 g q8h, 88.1%) and piperacillin/tazobactam (4.5 g q6h, 80.5%) as 0.5-hour infusions were nearly optimal, whereas ceftriaxone, ertapenem, and the fluoroquinolones had the lowest wCFR values. All regimens showed lower wCFRs for late-onset pneumonia than for HAP. Optimal wCFRs were found only with prolonged (3-hour) infusions of 2 g q8h for ceftazidime (94.5%) and meropenem (90.1%), whereas cefepime 2 g q8h achieved optimal wCFR with both a 0.5-hour infusion (93.1%) and a 3-hour infusion (95.3%).Results of this model suggest that standard doses of most antipseudomonal beta-lactams (cefepime, ceftazidime, and meropenem) had high probabilities of achieving optimal pharmacodynamic exposure as empiric therapy for HAP, whereas the low probabilities predicted from ceftriaxone, ertapenem, and the fluoroquinolones suggest that these agents would be inappropriate as monotherapy. For late-onset HAP, prolonged infusions of cefepime, ceftazidime, and meropenem offered the highest probabilities of achieving bactericidal exposure." @default.
• W2029795370 created "2016-06-24" @default.
• W2029795370 creator A5031928492 @default.
• W2029795370 creator A5090657231 @default.
• W2029795370 creator A5090740872 @default.
• W2029795370 date "2009-11-01" @default.
• W2029795370 modified "2023-10-10" @default.
• W2029795370 title "Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia" @default.
• W2029795370 cites W1501112436 @default.
• W2029795370 cites W1608647205 @default.
• W2029795370 cites W1852503640 @default.
• W2029795370 cites W1964915993 @default.
• W2029795370 cites W1978280070 @default.
• W2029795370 cites W1980567277 @default.
• W2029795370 cites W2007818273 @default.
• W2029795370 cites W2034302582 @default.
• W2029795370 cites W2052818550 @default.
• W2029795370 cites W2071583935 @default.
• W2029795370 cites W2079691262 @default.
• W2029795370 cites W2085793991 @default.
• W2029795370 cites W2094710544 @default.
• W2029795370 cites W2103780797 @default.
• W2029795370 cites W2104609410 @default.
• W2029795370 cites W2106210183 @default.
• W2029795370 cites W2106307190 @default.
• W2029795370 cites W2111882203 @default.
• W2029795370 cites W2117553136 @default.
• W2029795370 cites W2126184332 @default.
• W2029795370 cites W2131173790 @default.
• W2029795370 cites W2133979383 @default.
• W2029795370 cites W2136028041 @default.
• W2029795370 cites W2143024482 @default.
• W2029795370 cites W2147264575 @default.
• W2029795370 cites W2156273542 @default.
• W2029795370 cites W2158873221 @default.
• W2029795370 cites W2160331061 @default.
• W2029795370 cites W2162465279 @default.
• W2029795370 cites W2164281017 @default.
• W2029795370 cites W2164370556 @default.
• W2029795370 cites W2168147536 @default.
• W2029795370 cites W4211194064 @default.
• W2029795370 doi "https://doi.org/10.1016/j.clinthera.2009.11.026" @default.
• W2029795370 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20110018" @default.
• W2029795370 hasPublicationYear "2009" @default.
• W2029795370 type Work @default.
• W2029795370 sameAs 2029795370 @default.
• W2029795370 citedByCount "44" @default.
• W2029795370 countsByYear W20297953702012 @default.
• W2029795370 countsByYear W20297953702013 @default.
• W2029795370 countsByYear W20297953702014 @default.
• W2029795370 countsByYear W20297953702015 @default.
• W2029795370 countsByYear W20297953702016 @default.
• W2029795370 countsByYear W20297953702017 @default.
• W2029795370 countsByYear W20297953702018 @default.
• W2029795370 countsByYear W20297953702019 @default.
• W2029795370 countsByYear W20297953702020 @default.
• W2029795370 countsByYear W20297953702021 @default.
• W2029795370 countsByYear W20297953702022 @default.
• W2029795370 countsByYear W20297953702023 @default.
• W2029795370 crossrefType "journal-article" @default.
• W2029795370 hasAuthorship W2029795370A5031928492 @default.
• W2029795370 hasAuthorship W2029795370A5090657231 @default.
• W2029795370 hasAuthorship W2029795370A5090740872 @default.
• W2029795370 hasConcept C111113717 @default.
• W2029795370 hasConcept C112705442 @default.
• W2029795370 hasConcept C126322002 @default.
• W2029795370 hasConcept C2776520383 @default.
• W2029795370 hasConcept C2776968632 @default.
• W2029795370 hasConcept C2777050379 @default.
• W2029795370 hasConcept C2777184939 @default.
• W2029795370 hasConcept C2777637488 @default.
• W2029795370 hasConcept C2777858937 @default.
• W2029795370 hasConcept C2777914695 @default.
• W2029795370 hasConcept C2778193466 @default.
• W2029795370 hasConcept C2778266534 @default.
• W2029795370 hasConcept C2778368673 @default.
• W2029795370 hasConcept C2779375183 @default.
• W2029795370 hasConcept C2779631663 @default.
• W2029795370 hasConcept C42219234 @default.
• W2029795370 hasConcept C501593827 @default.
• W2029795370 hasConcept C523546767 @default.
• W2029795370 hasConcept C54355233 @default.
• W2029795370 hasConcept C71924100 @default.
• W2029795370 hasConcept C86803240 @default.
• W2029795370 hasConcept C89423630 @default.
• W2029795370 hasConcept C94665300 @default.
• W2029795370 hasConceptScore W2029795370C111113717 @default.
• W2029795370 hasConceptScore W2029795370C112705442 @default.
• W2029795370 hasConceptScore W2029795370C126322002 @default.
• W2029795370 hasConceptScore W2029795370C2776520383 @default.
• W2029795370 hasConceptScore W2029795370C2776968632 @default.
• W2029795370 hasConceptScore W2029795370C2777050379 @default.
• W2029795370 hasConceptScore W2029795370C2777184939 @default.
• W2029795370 hasConceptScore W2029795370C2777637488 @default.
• W2029795370 hasConceptScore W2029795370C2777858937 @default.
• W2029795370 hasConceptScore W2029795370C2777914695 @default.
• W2029795370 hasConceptScore W2029795370C2778193466 @default.
• W2029795370 hasConceptScore W2029795370C2778266534 @default.

• next